Mintek Pacemaker LV-T Benutzerhandbuch

Seite von 172
Stratos LV/LV-T Technical Manual  31 
Table 4: AVAIL CLS/CRT Complication-Free Rate at 
6 months – Stratos LV 
 
Category 
Number 
of 
Patients
% of 
Patients
Number of 
Complications
Complications 
per patient-
year 
Other Medical 
Worsening 
CHF 
2 2.7% 
0.03 
Repeat 
Ablation 
3 4.0% 
0.05 
Non-CHF 
cardiac 
symptoms 
3 4.0% 
0.05 
Other Medical 
3 4.0% 
0.05 
Total  
10 13.3% 
11 
0.17 
Total—All 
Patients and 
Categories 
19 25.3% 
24 
0.37 
Number of Patients = 75 Number of Patient-Years = 64.4 
 
The freedom from Stratos LV system-related and procedure-
related complications was 85.33%, with a one sided lower 95% 
confidence bound of 76.89%. Therefore, the procedure, lead and 
device related complication-free rate at 6 months met the pre-
specified acceptance criterion of equivalence (non-inferiority) 
within 10% of 85% (p = 0.0196). 
Observed Adverse Events 
Adverse events are classified as either observations or 
complications.  Observations are defined as clinical events that 
do not require additional invasive intervention to resolve.  
Complications are defined as clinical events that require 
additional invasive intervention to resolve. 
Of the 104 adverse events reported in the Stratos LV study 
groups, there have been 76 observations in 45 patients and 28 
complications in 20 patients with a cumulative enrollment 
duration of 64.4 patient-years.  26.7% of the enrolled Stratos LV 
patients have experienced a complication. The rate of 
complications per patient-year is 0.43.  60.0% of the enrolled 
study patients have a reported observation.  The rate of 
observations per patient-year is 1.18.